How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/her2-positive-carcinoma-of-breast.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

HER2-positive carcinoma of breast — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HER2-positive carcinoma of breast (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating HER2-positive carcinoma of breast, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Perjeta	pertuzumab	Roche	HER2/neu Receptor Antagonist [EPC]	Receptor tyrosine-protein kinase erbB-2	2012-01-01
Tykerb	LAPATINIB	Novartis	Kinase Inhibitor	Epidermal growth factor receptor	2007-01-01
Herceptin	Trastuzumab-Qyyp	Roche	HER2/neu receptor antagonist monoclonal antibody	HER2 (c-erbB2) proto-oncogene transmembrane receptor protein	1998-01-01
Herceptin	trastuzumab	Roche	Antibody-drug conjugate (ADC)	HER2 receptor, subdomain IV	1998-01-01
OGIVRI	TRASTUZUMAB-DKST	MYLAN GMBH	HER2/neu Receptor Antagonist [EPC]	Receptor tyrosine-protein kinase erbB-2
Perjeta	Perjeta	BioRay Pharmaceutical Co., Ltd.		Receptor tyrosine-protein kinase erbB-2
Herceptin	Herceptin	National Cancer Institute (NCI)		Receptor tyrosine-protein kinase erbB-2
Trastuzumab (Herceptin)	trastuzumab-herceptin	Pfizer Inc.		Receptor tyrosine-protein kinase erbB-2
Trastuzuma	Trastuzuma	Fudan University		Receptor tyrosine-protein kinase erbB-2, Tubulin beta

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Roche · 3 drugs in HER2-positive carcinoma of breast
Fudan University · 1 drug in HER2-positive carcinoma of breast
MYLAN GMBH · 1 drug in HER2-positive carcinoma of breast
BioRay Pharmaceutical Co., Ltd. · 1 drug in HER2-positive carcinoma of breast
Novartis · 1 drug in HER2-positive carcinoma of breast
Pfizer Inc. · 1 drug in HER2-positive carcinoma of breast
National Cancer Institute (NCI) · 1 drug in HER2-positive carcinoma of breast

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in HER2-positive carcinoma of breast:

Cite this brief

Drug Landscape (2026). HER2-positive carcinoma of breast — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/her2-positive-carcinoma-of-breast. Accessed 2026-06-10.

HER2-positive carcinoma of breast full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing